A Novel Preclinical Tool for Evaluating CD3/BCMA T Cell-Engaging Antibodies Efficacy Based on a Spontaneous Systemic Lupus Erythematosus Model
June 08, 2026
A Novel Preclinical Tool for Evaluating CD3/BCMA T Cell-Engaging Antibodies Efficacy Based on a Spontaneous Systemic Lupus Erythematosus Model
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease driven by dysregulated B-cell activation, leading to excessive autoantibody production and immune complex deposition in tissues. A key mediator in this process is B-Cell Maturation Antigen (BCMA), which is highly expressed on plasma cells and supports their survival and antibody secretion, making it an emerging therapeutic target in SLE.
Teclistamab is a humanized bispecific T-cell engager antibody targeting BCMA and CD3, redirecting T cells to selectively eliminate BCMA⁺ plasma cells. To evaluate this therapeutic strategy, GemPharmatech has developed a novel spontaneous SLE model using BALB/c-hBAFF/hCD3/hBCMA humanized mice.
In this model, Teclistamab treatment significantly reduced anti-dsDNA antibodies, total IgG levels, and BCMA⁺ plasma cell populations, demonstrating effective disease modulation consistent with clinical observations.
Download
Teclistamab is a humanized bispecific T-cell engager antibody targeting BCMA and CD3, redirecting T cells to selectively eliminate BCMA⁺ plasma cells. To evaluate this therapeutic strategy, GemPharmatech has developed a novel spontaneous SLE model using BALB/c-hBAFF/hCD3/hBCMA humanized mice.
In this model, Teclistamab treatment significantly reduced anti-dsDNA antibodies, total IgG levels, and BCMA⁺ plasma cell populations, demonstrating effective disease modulation consistent with clinical observations.